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Experimental autoimmune encephalomyelitis (EAE) induced by sensitization with myelin oligodendrocyte glycoprotein (MOG) is
a T cell-dependent autoimmune disease that reproduces the inﬂammatory demyelinating pathology of multiple sclerosis. We
report that an encephalitogenic T cell response to MOG can be either induced or alternatively suppressed as a consequence of
immunological cross-reactivity, or “molecular mimicry” with the extracellular IgV-like domain of the milk protein butyrophilin
(BTN). In the Dark Agouti rat, active immunization with native BTN triggers an inﬂammatory response in the CNS characterized
by the formation of scattered meningeal and perivascular inﬁltrates of T cells and macrophages. We demonstrate that this
pathology is mediated by a MHC class II-restricted T cell response that cross-reacts with the MOG peptide sequence 76–87,
IGEGKVALRIQN (identities underlined). Conversely, molecular mimicry with BTN can be exploited to suppress disease activity
in MOG-induced EAE. We demonstrate that not only is EAE mediated by the adoptive transfer of MOG74–90 T cell lines markedly
ameliorated by i.v. treatment with the homologous BTN peptide, BTN74–90, but that this protective effect is also seen in actively
induced disease following transmucosal (intranasal) administration of the peptide. These results identify a mechanism by which
the consumption of milk products may modulate the pathogenic autoimmune response to MOG. The Journal of Immunology,
2000, 165: 2859–2865.
T
he etiology of multiple sclerosis (MS)
4 is obscure but is
believed to involve environmental factors that disrupt im-
munological self-tolerance to CNS myelin in genetically
susceptible individuals (1). The selective activation and expansion
of myelin-speciﬁc T and B cells in MS patients supports this con-
cept (1, 2), but the identity and mode of action of the environmen-
tal factors that initiate or exacerbate this autoimmune response
remain unknown.
A major target for the pathogenic autoimmune response in MS
and its animal model, experimental autoimmune encephalomyeli-
tis (EAE), is the myelin oligodendrocyte glycoprotein (MOG).
MOG is the only myelin autoantigen known to induce both a de-
myelinating autoantibody response (3, 4) and an encephalitogenic
CD4
1 T cell response (5–8) in animals with EAE. The demyeli-
nating potential of the MOG-speciﬁc Ab response has been studied
extensively both in vivo and in vitro (4, 9, 10), and, in MOG-
induced EAE, this humoral response acts synergistically with the
encephalitogenic T cell response to induce a demyelinating pathol-
ogy similar to that in MS (4, 11–14). Although the encephalito-
genic MOG-speciﬁc CD4
1 T cell response initiates the recruit-
ment of immune effector cells into the CNS and disrupts the blood
brain barrier, demyelination in the rat is dependent on the presence
of anti-MOG autoantibodies (4). These Abs bind to MOG exposed
on the myelin surface (15) and mediate demyelination by a com-
bination of complement and cell-mediated immune effector mech-
anisms (16–18). The observation that both MOG-speciﬁc T cell
(19, 20) and Ab responses (21) are enhanced relative to other my-
elin Ags in MS suggests that demyelination involves a similar
combination of immune effector mechanisms in the human dis-
ease. A concept supported by the recent demonstration that anti-
MOG-Abs colocalize with myelin debris in actively demyelinating
MS lesions (13, 22). However, the mechanism(s) that may initially
disrupt self-tolerance to MOG in MS are obscure.
Intriguingly, sequence homologies involving its extracellular Ig-
like domain (MOG
Igd) identiﬁed MOG as a member of an ex-
tended family of “B7-like”proteins (23). Of particular interest was
the ﬁnding that the highest level of sequence identity, ;50%, was
with a homologous extracellular Ig domain of butyrophilin (BTN)
(24), a major protein of the milk fat globule membrane (MFGM)
(25, 26). This observation led us to speculate that immunological
cross-reactivity or “molecular mimicry” with BTN may inﬂuence
the function of the MOG-reactive autoimmune repertoire.
In the current study, we report that this is indeed the case. In the
context of a permissive MHC haplotype, we show that the CD4
1
T cell response to BTN and MOG is mutually cross-reactive.
Therefore, sensitization with native BTN can initiate an inﬂam-
matory response in the CNS mediated by a class II MHC-restricted
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treatment with BTN peptide can abrogate MOG-induced EAE. The
observation that transmucosal exposure to a BTN peptide can
modulate disease activity in MOG-induced EAE suggests that, in
the context of an appropriate HLA haplotype, dietary exposure
to BTN may modulate the pathogenic autoimmune response to
MOG in MS.
Materials and Methods
Animals and Ags
Dark Agouti (DA) and Brown Norway (BN) rats (120–200 g) were ob-
tained from Charles River Breeding Laboratories (Sulzfeld, Germany), and
Lewis (LEW) rats were obtained from the animal facility of the Max-
Planck Institute for Biochemistry (Martinsried, Germany). CFA, IFA, and
heat-killed Mycobacterium tuberculosis (H37Ra) were purchased from
Difco (Detroit, MI). Puriﬁed protein derivative was purchased from the
State Serum Institute (Copenhagen, Denmark). Recombinant MOG
Igd
(amino acids 1–120) (12) and BTN
IgV (amino acids 27–144 notation in-
cluding signal sequence) (26) corresponding to the N-terminal Ig-like do-
mains of the two proteins with a C-terminal hexahistidine tag were ex-
pressed in Escherichia coli. The recombinant proteins were puriﬁed by
chromatography on Ni-NTA agarose to a purity of .95% as assessed by
SDS-PAGE (Qiagen, Chatsworth, CA) and stored at 220°C. MFGM was
puriﬁed from fresh bovine milk as described previously (25). Synthetic
peptides were purchased from Genosys (Cambridge, U.K.).
Immunization protocols and generation of Ag-speciﬁc T cell
lines
Rats were immunized s.c. at the base of the tail with 100 mg Ag emulsiﬁed
in CFA containing 225 mg of heat-killed M. tuberculosis (H37Ra) in a total
volume of 100 ml. Ag-speciﬁc T cell lines were generated as described
previously (12). Brieﬂy, the draining lymph nodes were removed 10 days
postimmunization (d.p.i.), and a single cell suspension was cultured for
72 h at a concentration of 10
7 cells/ml in DMEM supplemented with glu-
tamine, penicillin, streptomycin, sodium pyruvate, essential amino acids
(Life Technologies, Rockville, MD), and 1% rat serum in the presence of
the selecting Ag (20 mg/ml). T cell blasts were then isolated by density
gradient centrifugation and propagated for a further 5–10 days in medium
containing IL-2. Ag-speciﬁc T cell lines were subsequently maintained by
cycles of Ag-speciﬁc restimulation using irradiated (5000 rad) syngeneic
thymus cells as APCs, followed by expansion in IL-2-containing medium.
Cytoﬂuorometric analysis was performed using samples of 2 3 10
5
viable cells washed with PBS containing 0.2% BSA and 10 mM NaN3 and
incubated with the primary mAb for1ho nice. After washing, the cells
were stained with ﬂuorescein-conjugated goat anti-mouse IgG (Dianova,
Hamburg, Germany) for1ho nice. After removing unbound ﬂuorescein-
conjugate by washing, the cells were analyzed using a ﬂuorescence-acti-
vated cell sorter (FACScan; Becton Dickinson, Heidelberg, Germany). A
live gate was obtained by incubating the cells in PBS containing propidium
iodide.
Proliferation assays were performed in ﬂat-bottom 96-well tissue cul-
ture plates in a total volume of 200 ml using either 5 3 10
5 lymph node
cells, or 2 3 10
4 T line cells plus 5 3 10
5 syngeneic, irradiated (5000 rad)
thymus cells as APCs. Ag-speciﬁc proliferation was assessed by the in-
corporation of [
3H]thymidine (10 mCi/well) during the ﬁnal 16 h of a 72-h
culture period using a Packard (Meriden, CT) Matrix 96 Direct b counter.
EAE induction and treatment
Female DA rats (6–8 wk old) were treated intranasally daily for a period
of 10 days with a dose of 50 mg of Ag (1 mg/ml in water), which was
injected using a micropipette (25 ml per nostril). Three days after the last
intranasal application of Ag, the animals were injected with 100 mgo f
MOG
Igd in IFA. Adoptive transfer experiments were performed using ac-
tivated T cell blasts isolated after 72 h restimulation with Ag in vitro. The
T cell blasts were suspended in a volume of 1 ml DMEM and injected into
the tail vein of female DA rats (6–8 wk old). Treatment with high-dose
soluble Ag was performed using 500 ml of Ag (2 mg/ml in DMEM) in-
jected in the tail vein 2 and 4 days after T cell transfer. Animals were
weighed and examined daily for clinical signs of EAE that was scored on
a scale of 0–5 as described previously.
Histopathological analysis
Histological evaluation was performed on paraformaldehyde-ﬁxed, paraf-
ﬁn-embedded sections of brains and spinal cords sampled at various time
points of disease. Parafﬁn sections were stained with hematoxylin-eosin,
Luxol fast blue, and Bielschowsky silver impregnation to assess inﬂam-
mation, demyelination, and axonal pathology. In adjacent serial sections,
immunohistochemistry was performed with Abs against macrophages/ac-
tivated microglia (ED1; Serotec, Oxford, U.K.) or T cells (W3/13; Seralab,
Sussex, U.K.). Bound primary Ab was detected with a biotin-avidin tech-
nique as previously described in detail (27). Control sections were incu-
bated in the absence of primary Ab or with nonimmune rabbit serum.
Results
Sensitization with BTN induces a strain-speciﬁc inﬂammatory
response in the CNS
LEW, BN, and DA rats were immunized with either MFGM, or
alternatively BTN
IgV in CFA and monitored for the development
of clinical and/or histopathological evidence of EAE. Strikingly,
although neither immunogen induced clinical disease in these rat
strains, histopathological analysis identiﬁed a subclinical inﬂam-
matory response in the CNS of DA rats that was absent in DA
controls immunized with PBS/CFA. This pathologic response was
characterized by the formation of scattered meningeal and perivas-
cular inﬁltrates of T cells and macrophages throughout the CNS
(Fig. 1a). This is in contrast to the pathology of MOG-induced
EAE in the rat that is dominated by Ab-mediated demyelination
(28). In contrast, neither immunogen induced any CNS pathology
in the other two rat strains. Moreover, no pathology developed in
the CNS of DA rats immunized with PBS/CFA. These observa-
tions indicate that BTN
IgV, a major component of MFGM, can act
as a strain-speciﬁc encephalitogen in the rat.
MOG-speciﬁc T cells cross-react with a deﬁned BTN peptide in
the DA rat
To test the hypothesis that molecular mimicry with MOG
Igd at the
level of the T cell response was responsible for the CNS pathology
induced by BTN, we investigated the ability of BTN and synthetic
BTN peptides to stimulate a panel of encephalitogenic class II
MHC-restricted MOG-speciﬁc T cell lines (TCL) derived from
LEW (MHC RT1
l), BN (MHC RT1
n), and DA (MHC RT1
av1)
rats. The encephalitogenic epitopes recognized by these TCLs are
strain-speciﬁc and together span 70% of the MOG
Igd sequence
(Table I).
In agreement with the inability of BTN
IgV to mediate an en-
cephalitogenic response in either LEW or BN rats, MOG-speciﬁc
TCLs derived from these strains did not proliferate in response to
either BTN
IgV or synthetic BTN
IgV peptides in vitro. In contrast,
DA MOG-speciﬁc TCLs proliferated in response to BTN
IgV in the
presence of syngeneic APCs. Using a panel of overlapping syn-
thetic peptides, we demonstrated that this cross-reactive response
was restricted to the overlapping BTN peptides BTN63–87 and
BTN76–100 (Fig. 2a).
The overlapping sequence of these peptides spans an encepha-
litogenic MOG T cell epitope for the DA rat, the peptide sequence
MOG76–87, suggesting that molecular mimicry was restricted to
this epitope and did not involve a second epitope located within
MOG96–107 (Fig. 2a; Table I; Stefferl and Schubart, unpublished
observations). We investigated this further using synthetic peptides
corresponding to amino acids 74–90 of the IgV-like domains of
the two Ags. Strikingly both MOG74–90 and BTN74–90 stimulated
the MOG-speciﬁc TCL to a similar extent, inducing a proliferative
response similar to that obtained with the recombinant Ag and the
longer peptides (Fig. 2a).
Active immunization with BTN induces an encephalitogenic
MOG-reactive T cell response
Although the above observations demonstrate that the DA MOG-
speciﬁc T cell response exhibits molecular mimicry with BTN in
2860 BUTYROPHILIN-INDUCED EAEvitro, it remained uncertain whether this was responsible for the
inﬂammatory pathology induced by active immunization with
BTN in vivo. Therefore, we examined the BTN-speciﬁc T cell
repertoire for evidence of a cross-reactive and encephalitogenic
response to MOG74–90 using short-term TCLs obtained from
BTN
IgV immunized donors. Ag-speciﬁc TCLs were selected in
vitro using a combination of the peptides BTN63–87 and BTN76–
100 as the selecting Ag. After two rounds of restimulation in vitro,
the encephalitogenic capacity of the TCLs was assessed by adop-
tive transfer into naive syngeneic recipients.
The i.v. injection of 5 3 10
6 to 10
7 T line cells induced an
intense inﬂammatory response in the CNS of all recipients (Fig.
1b), associated with weight loss and hind limb paraparesis. Immu-
nohistochemical analysis of the lesions revealed that they con-
sisted of large numbers of T cells concentrated in the perivascular
space. Migration of inﬁltrating T cells into the parenchyma was
restricted and the recruitment of ED1
1 macrophages into the CNS
was minimal (Fig. 1, c and d), a pathology similar to that described
previously in the Lewis rat following the adoptive transfer of
MOG-speciﬁc T cells (6).
The observation that BTN63–87/BTN76–100-selected TCLs pro-
liferate in vitro in response to MOG74–90 and MOG
Igd, as well as
the selecting peptides and BTN, conﬁrmed that the pathogenicity
of this T cell population could be attributed to cross-reactivity with
MOG (Fig. 2b). FACS analysis revealed that the TCLs consisted
predominantly (.90%) of CD4
1, CD45RO
2, abTcR
1 T cells
(data not presented), and blocking assays using the mAbs OX6
(RT1B), OX17 (RT1D), and OX18 (class I MHC) demonstrated
that their Ag-speciﬁc response to B74–90 and M74–90 was class II
MHC (RT1B)-restricted (Fig. 2c). Therefore, BTN can be pro-
cessed and presented in vivo to stimulate a mutually cross-reactive
and encephalitogenic class II MHC-restricted T cell response to
MOG in the DA rat.
BTN peptide suppresses adoptively transferred MOG-EAE
It is now appreciated that molecular mimicry can induce either a
pathogenic autoimmune response or, conversely, tolerance, depend-
ing on variables such as the route of sensitization, dose, and adjuvant
effects (29). This is of particular relevance for peptides derived from
ingested Ags, as these will cross the gut mucosal surface and provide
tolerogenic signals in the periphery (30, 31). Therefore, could mim-
icry with BTN be exploited to suppress an autoaggressive MOG-
reactive T cell response and abrogate clinical disease in EAE?
The tolerogenic potential of BTN74–90 was ﬁrst investigated in
EAE induced by the adoptive transfer of MOG74–90-speciﬁc T
cells. In the DA rat, a dose of 5 3 10
6 MOG74–90-speciﬁc T cells
induced a maximal clinical score of 2.5 6 0.3 four days after
transfer. Disease severity was dramatically attenuated following
i.v. treatment with high-dose BTN74–90 given on days 2 and 4
following T cell transfer (Fig. 3). The same treatment protocol
using the nominal MOG peptide ligand MOG74–90 was even more
effective and completely abrogated clinical disease (Fig. 3). This
differential in vivo effect was not reﬂected by the in vitro prolif-
erative response of MOG74–90-speciﬁc T cells to MOG74–90 and
BTN74–90, which was similar over a wide concentration range
(Fig. 2d). We are currently investigating whether this reﬂects dif-
ferences in the pharmacological characteristics of the peptides in
vivo, or differential effects of the BTN peptide on individual
MOG74–90-speciﬁc T cell clones within the TCLs.
However, would transmucosal exposure to the BTN peptide
have a signiﬁcant impact on the course of EAE-induced by active
immunization with MOG
Igd? This disease model reproduces the
complex immunopathology of MS and is mediated by a combina-
tion of both Ab and T cell-dependent effector mechanisms, includ-
ing an encephalitogenic T cell response directed against two dis-
tinct epitopes (Table I; Stefferl and Schubart, unpublished
observations). In view of the complex immunopathogenesis of this
model and that only one T cell epitope exhibits molecular mimicry
with BTN, it was not surprising that intranasal treatment with any
of the peptides when given individually (MOG93–110, MOG74–90,
or BTN74–90) was unable to completely suppress clinical disease.
Controls pretreated with OVA developed a biphasic disease char-
acterized by an initial episode of EAE that was rapidly followed by a
severe relapse that was normally fatal by day 25 p.i. (Fig. 4a). Nasal
FIGURE 1. Representative spinal
cord histopathology of DA rats induced
by BTN. a, Active immunization with
BTN
IgV; b–d, Adoptive transfer of 10
7
BTN 74–90-speciﬁc T line cells. a, Virgin
female DA rats immunized with BTN
IgV
develop a perivascular inﬂammatory in-
ﬁltrate consisting of mononuclear cells
(between arrowheads). DA rats immunized
with MFGM/CFA developed similar le-
sions. b, Adoptive transfer of BTN 74–90-
speciﬁc T cells induced the formation of
multiple perivascular inﬂammatory inﬁl-
trates (small arrowheads; the asterisk indi-
cates the inﬁltrate, which is shown in c and
d at higher magniﬁcation) consisting of
large numbers of T cells (c) but relatively
few ED1
1 macrophages (d). Invasion into
the parenchyma was minimal. (Magniﬁca-
tion: a, c, and d, 3270; b, 335.)
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failed to delay disease onset or stop disease progression beyond day
15, as demonstrated in Fig. 4b for animals treated with MOG93–110.I n
contrast, the effect of treatment with combinations of either MOG93–110
and BTN74–90,o rM O G 93–110 and MOG74–90 was far more effective and
both combinations of peptides delayed disease onset, penetrance, and se-
verity (Fig. 4c). This effect was clearly seen 20 d.p.i. when all animals in
the control group pretreated with OVA were in relapse with a mean clin-
ical score of 3.5 6 0.32 (n 5 6, Fig. 4c). In contrast, at this time point,
only two rats treated with MOG93–110/BTN74–90 combination (n 5 5)
had developed EAE (grades 1 and 2). A similar level of protection was
also seen following intranasal pretreatment with the combination
MOG93–110/MOG74–90 (data not shown). Therefore, the BTN peptide
could be used interchangeably with the corresponding MOG epitope to
modify the severity of actively induced MOG-EAE.
Discussion
In this study, we demonstrate that, as a consequence of molecular
mimicry, BTN, a common dietary Ag, can modulate the autoim-
mune T cell response to MOG, a major target in the immunopatho-
genesis of EAE and MS. This observation extends the concept of
FIGURE 2. MOG and BTN provoke a mutually cross-reactive T cell response. T cell lines were derived from DA rats immunized with either (a) MOG
Igd
or (b) BTN
IgV. Epitope mapping using sets of overlapping synthetic peptides spanning the homologous Ig-domains of BTN or MOG identiﬁed a cross-
reactive T cell response to an epitope located between amino acids 74 and 90. a, DA MOG-speciﬁc T cell lines exhibit a limited proliferative response to
BTN
IgV that is similar to that obtained using the peptides BTN63–87 and BTN76–100, their overlapping sequence BTN74–90 and its MOG homologue,
MOG74–90. b, A similar cross-reactive response was found when T cells speciﬁc for the epitope BTN74–90 were selected from the draining lymph nodes
of BTN
IgV immunized DA rats. However, in this case, although both MOG
Igd and the peptides induced a substantial proliferative response, BTN
IgV was
relatively poorly processed and presented to the T cells in vitro. c, Recognition of their cognate peptide by MOG74–90-speciﬁc (f) and BTN74–90-speciﬁc
(M) TCLs is restricted by class II MHC (I-A). Addition of the mAb OX6 (anti-I-A), but not mAbs OX 17 (anti-I-E) or OX18 (anti-class I MHC), blocks
proliferation in vitro (mAb concentration 10 mg/ml) The puriﬁed OX mAbs were kindly provided by Dr. R. Weissert, Stockholm. d, The peptides MOG74–90
and BTN74–90 stimulate MOG74–90-speciﬁc T cells to a similar extent over a broad range of peptide concentrations.
Table I. Sequence homologies between encephalitogenic MOG T cell epitopes and BTN
Strain RT1 Peptide Amino Acid Sequence Identity (%)
LEW
a l MOG1–20 GQF RVI GPG HPI RAL VGD EA 55 BTN1–20 APF DVI GPQ EPI LAV VGE DA
MOG35–55 MEV GWY RSP FSR VVH LYR NGK 33 BTN35–55 MEL RWF REK VSP AVF VSR EGQ
BN
b n MOG24–44 CRI SPG KNA TGM EVG WYR SPF 47 BTN24–44 CRL SPN VSA KGM ELR WFR EKV
DA
b avl MOG74–94 ESI GEG KVA LRI QNV RFS DEG 57 BTN74–94 DHI AEG SVA VRI QEV KAS DDG
MOG89–109 RFS DEG GYT CFF RDH SYQ EEA 52 BTN89–109 KAS DDG EYR CFF RQD ENY EEA
a Data taken from Ref. 6.
b Data for the identity of the BN and DA epitopes was obtained from our unpublished data.
2862 BUTYROPHILIN-INDUCED EAEmolecular mimicry to include dietary components as potential eti-
ological factors in the immunopathogenesis of MS, which is a
hypothesis that can now be tested and which may provide a mech-
anistic basis for epidemiological studies that link the consumption
of milk and milk products to the prelevance of MS (32–34).
Immunologic cross-reactivity, or molecular mimicry, involving
microbial Ags and self is often discussed as one mechanism that
may break self-tolerance to CNS myelin autoantigens in MS (35–
37). This apparent lack of Ag speciﬁcity is a direct consequence of
the degeneracy of TCR recognition of MHC/peptide complexes,
resulting in the recognition of an extensive hierarchy of agonist
and antagonist peptide ligands by a single TCR (38). Therefore,
human T cell clones speciﬁc for MBP can be activated in vitro
with synthetic viral peptides (39), and immunization with synthetic
microbial peptides can induce an autoaggressive T cell response in
vivo (35–37). However, whether or not mimicry involving micro-
bial pathogens and myelin leads to autoaggression during the nat-
ural course of infection remains unknown. Our present study ex-
tends this concept to include mimicry with dietary Ags as a
potential etiological factor in autoimmune diseases of the nervous
system.
Autoaggression induced by BTN is T cell-mediated and re-
stricted by class II MHC. This limits the number of MHC haplo-
types that are permissive for the induction of an encephalitogenic
response to MOG. In our current study, we observed that only one
of three rat haplotypes supported this response. In the context of
the permissive RT1
av1 haplotype, the cross-reactive T cell epitopes
of MOG and BTN share a core region (amino acids 74–86) of
which 8 of 12 residues are identical (Table I). Although at least
two other encephalitogenic epitopes of MOG in the rat exhibit
similar levels of gross sequence identity with BTN, this is not
sufﬁcient to support a proliferative/encephalitogenic T cell re-
sponse (Table I). However, it is to be anticipated that non-MHC
genes and environmental factors, such as the intestinal ﬂora, will
also play a role in determining the penetrance of this effect and the
pathogenicity of the BTN/MOG-reactive T cell response. These
observations suggest that, despite the extensive sequence identity
that exists between the two proteins, only a limited number of
human MHC haplotypes may be permissive for a similar cross-
reactive T cell response.
However, although active immunization with BTN in CFA in-
duces a pathogenic autoimmune response, this is not the route by
which the immune system is exposed normally to this Ag. BTN is
a sexually dimorphic protein that is only expressed in the lactating
mammary gland (23, 26, 40), and, therefore, with exception of
lactating females, the only route by which BTN-derived peptides
can inﬂuence or trigger an immune response is via the diet. It is
now known that immunogenic peptides can cross the gut mucosal
surface to be presented to T cells in the periphery within hours of
ingestion (30). This directly inﬂuences the selection, survival, and
function of the T cell repertoire and contributes to “oral tolerance,”
the systemic suppression of potentially inﬂammatory responses to
dietary Ags (29–31, 41, 42).
Applying Ag intranasally provides an alternative route to study
the induction of transmucosal tolerance that avoids possible deg-
radation of the target peptide in gastrointestinal tract (43, 44). In
both cases, Ag-speciﬁc tolerance involves multiple mechanisms
including “suppressor” T cell responses, anergy, and activation-
induced cell death; the relative contribution of each depending on
factors such as dose, timing, and the identity of the Ag (29–31,
41–44). In the current study, we demonstrate that, despite the im-
munopathological complexity of MOG-induced EAE, intranasal
application of a 1:1 mixture of the encephalitogenic MOG pep-
tides, MOG74–90 and MOG93–110, has a dramatic effect on the
severity and clinical course of MOG-induced EAE. Moreover, this
effect is maintained when MOG74–90 is replaced by its BTN ho-
mologue, BTN74–90. The mechanistic details responsible for this
clinical effect are currently being analyzed, but these results pro-
vide the ﬁrst indication that transmucosal sensitization to a BTN
peptide can modulate the effector T cell response to MOG. A sug-
gestion supported by our observation that treatment with high
doses of the BTN peptide also suppresses EAE mediated by the
adoptive transfer of MOG74–90-speciﬁc T cells (45).
We anticipate that a similar tolerogenic effect may also occur in
the adult following the consumption of bovine milk products, in
FIGURE 4. Intranasal vaccination with BTN peptide ameliorates disease activity in MOG-induced EAE. DA rats were pretreated by intranasal vacci-
nation as described in the text with (a) OVA (n 5 6), (b) MOG93–110 (n 5 6), or (c) a combination of MOG93–110 and BTN74–90 (n 5 5). The experiment
was terminated on day 20 postimmunization, by which time point the entire control group had developed severe neurological deﬁcits. Treatment with a
combination of MOG93–110 and BTN74–90 completely abolished the initial phase of disease and had a signiﬁcant effect on later disease activity reducing
the mean clinical score from 3.5 6 0.32 to ,1.0 on day 20.
FIGURE 3. High-dose BTN peptide suppresses MOG74–90-induced
EAE. DA rats were injected with a dose of 5 3 10
6 MOG74–90-speciﬁc T
cells that induced severe clinical disease starting from day 4 posttransfer
(F). Intravenous administration of 1 mg BTN74–90 (f)o rM O G 74–90 (l)
2 and 4 days after T cell transfer signiﬁcantly inhibited disease. Injections
were performed under light ether anesthesia; control animals were treated
with OVA. p, p , 0.05; Duncan’s post hoc test.
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BTN itself, but also suppress cross-reactive and potentially en-
cephalitogenic MOG-reactive T cell responses. However, such an
effect will require a permissive MHC class II haplotype and be
further complicated by factors effecting the degradation and uptake
of BTN peptides in the gastrointestinal tract before its immuno-
logical processing and presentation. However, the mechanisms re-
sponsible for oral tolerance are poorly developed at birth, and, in
the neonate, feeding Ags may initially prime the immune system
rather than inducing tolerance, oral tolerance only developing if
feeding is continued beyond a critical age (31). In the case of an
autoantigen, this raises the possibility that neonatal exposure may
enhance disease susceptibility later in life. This was clearly seen in
rats fed MBP for a limited period immediately postpartum and
then subsequently immunized with MBP in CFA in adulthood
(46). These animals not only exhibited no tolerance to MBP-in-
duced EAE, but also developed more severe disease than control
littermates. In contrast, feeding MBP to adult rats induced oral
tolerance and suppressed MBP-induced EAE (46). The role that
timing of exposure and the differential effects of syngeneic BTN as
opposed to xenogeneic BTN have on the T cell response to MOG
is currently under investigation in BTN
2/2 and wild-type mice.
Intriguingly, the frequency of seropositive responders to milk
proteins peaks in childhood and declines as puberty approaches
(47), a time frame similar to that reported for the role of the en-
vironmental factors in the etiology of MS (1, 48). Moreover, ep-
idemiological studies have identiﬁed an association between the
consumption of milk and the prevalence of MS (32–34). However,
whether or not this is related to molecular mimicry between BTN
and MOG must remain a matter of speculation. Indeed, milk in the
diet is only one of many environmental factors related to the prev-
alence of MS (48). Moreover, this simple explanation neglects the
existence of multiple BTN homologues that are encoded together
with BTN telomeric of the nonclassical class 1 MHC locus (23).
Mimicry involving the N-terminal domains of these proteins,
which are expressed in a wide variety of tissues, may also inﬂu-
ence the composition and function of the BTN/MOG repertoire.
In conclusion, we identify BTN as an Ag that can inﬂuence the
clinical outcome of autoimmune responses to MOG, an important
antigenic target in EAE and MS. Modulation of the MOG-speciﬁc
repertoire as a consequence of molecular mimicry with this dietary
Ag BTN may be a signiﬁcant factor in determining the role MOG
plays as a target Ag in the immunopathogenesis of MS. Identiﬁ-
cation of those MHC haplotypes permissive for a cross-reactive T
cell response between MOG and BTN may provide a strategy to
identify those at risk of developing encephalitogenic responses to
MOG following premature exposure to BTN.
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